XIAP and Crohn disease: Given the strong genetic link between XIAP deficiency and inflammatory diseases, including Crohn’s disease, plus poor clinical outcomes for patients bearing deleterious XIAP mutations, we explored inhibition of RIP1-dependent cell death as a therapeutic option.